Prehospital Recognition and Identification of Unspecific Symptoms

Completed

• Conditions: Serious Condition; Morality

• Registration Number: NCT03089359
• Lead Sponsor: Karolinska Institutet

Brief Summary

This study evaluates the predictive value of soluvent urokinase plasminogen activator receptor (suPAR) and lactate with respect to serious conditions among patients presenting to the EMS with unspecific symptoms.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2015-05-04
• Study First Submitted: 2017-03-20
• Study First Submitted QC: 2017-03-20
• Study First Posted: 2017-03-24
• Status Verified: 2021-03
• Primary Completion: 2021-03-23
• Study Completion: 2021-03-23
• Last Update Submitted: 2021-03-24
• Last Update Posted: 2021-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 414

Inclusion Criteria

• Unspecific symptoms (not feeling well, decreased general health condition, unable to cope with usual daily activities, feeling weak)
• Normal vital signs
• Transported to ED
• Able to give informed consent/ Next of kin gives informed consent

Read More

Exclusion Criteria

• Specific symptoms
• under 18 years of age
• Stays home / other caregiver than ED
• Referral from caregiver
• No personal numer (social security number)

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serious condition	During medical care event	Predefined serious condition

Secondary Outcome Measures

Name	Time	Method
Mortality	24hours and 30 days	24h and 30 day mortality

Trial Locations

Locations (2)

Karolinska Institute; 🇸🇪 Stockholm, Sweden

Helsinki University; 🇫🇮 Helsinki, Finland